首页膀胱肿瘤治疗及预后证据详情

Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer

原文: 2018 年 发布于 Eur J Nutr 11 卷 第 2 期 A661-A661 浏览量:479次

作者: Masuda N. Ogawa O. Park M. Liu A. Y. Goodison S. Dai Y. Kozai L. Furuya H. Lotan Y. Rosser C. J. Kobayashi T.

作者单位: Department of Urology, Pengzhou People's Hospital, Chengdu, Sichuan, China. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China. ICU, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China. Department of Urology, Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China. Department of Anesthesiology (Operating Room), Pengzhou People's Hospital, Chengdu, Sichuan, China. Department of Orthopedics, Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China. Department of Gastrointestinal Surgery, Pengzhou People's Hospital, Chengdu, Sichuan, China. Department of Laboratory, Pengzhou People's Hospital, Chengdu, Sichuan, China.

归属分类: 膀胱肿瘤治疗及预后证据

DOI: 10.3389/fonc.2022.1024739

关键词: Aged Aged 80 and over *Biomarkers Tumor Cluster Analysis Cohort Studies Female Gene Expression Profiling Humans Immunohistochemistry Male Middle Aged Mutation Neoplasm Invasiveness Neoplasm Staging Neoplasms Basal Cell/*diagnosis/genetics/*metabolism/mortality Prognosis Survival Analysis Tissue Array Analysis Urinary Bladder Neoplasms/*diagnosis/genetics/*metabolism/mortality Biomarker Bladder cancer

文献简介

Objective: The aim of the study was to systematically review the relevant studies to evaluate the prognosis of primary and progressive muscle-invasive bladder cancer (MIBC) after radical cystectomy (RC) and provide a clue for the timing of RC in patients with progressive MIBC early at the time of high-risk non-muscle-invasive bladder cancer (NMIBC). Material and methods: PubMed, MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials were searched for eligible studies. We extracted hazard ratios (HRs) of overall survival (OS) and cancer-specific survival (CSS) and deaths at 5 and 10 years for each study and performed the meta-analysis using Review Manager 5.3. Results: A total of 11 retrospective studies with 4102 patients were included in the meta-analysis. The pooled analysis suggested a similar CSS (HR: 1.18; 95% CI, 0.74, 1.87; p = 0.50) and OS (HR: 1.15; 95% CI, 0.82, 1.61; p = 0.43) between primary and progressive MIBC patients treated with RC. The results further indicated no significant differences between the two populations in terms of 5-year CSS rate (OR: 1.32; 95% CI, 0.90, 1.95; p = 0.16), 10-year CSS rate (OR: 0.83; 95% CI, 0.37, 1.83; p = 0.64) as well as 5-year OS rate (OR: 1.02; 95% CI, 0.66, 1.56; p = 0.94). Subgroup analysis according to the starting point of follow-up showed similar outcomes. Conclusion: The meta-analysis demonstrates comparable CSS and OS in patients with primary and progressive MIBC following RC. Novel risk stratifications and prospective trials are urgently needed to investigate the prognosis after RC of these two groups of patients, which could finally aid clinician decision making and select patients who would actually benefit from early RC.

热门文献